Evidence map›Paper›PMID 31819401›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2019

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.

Afisi S Ismaila, Nancy Risebrough, Melanie Schroeder, Dhvani Shah, Alan Martin, Emma C Goodall, Kerigo Ndirangu, Gerard Criner, Mark Dransfield, David Mg Halpin and 2 more

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02164513 (A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02164513 phase3completednot on this map

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorGlaxoSmithKlineRan2014 to 2017Enrolled10,355ConditionsPulmonary Disease, Chronic ObstructiveArmsfluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial.International journal of chronic obstructive pulmonary disease · 2022
    Trial
  2. Trial
  3. Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK.International journal of chronic obstructive pulmonary disease · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline plc, Collegeville, PA, USA.ORCID 0000-0002-2876-8308
Nancy RisebroughICON Health Economics, ICON plc, Toronto, ON, Canada.
Melanie SchroederValue Evidence and Outcomes, GlaxoSmithKline plc, Brentford, UK.ORCID 0000-0003-0338-1331
Dhvani ShahICON Health Economics, ICON plc, New York, NY, USA.
Alan MartinValue Evidence and Outcomes, GlaxoSmithKline plc, Uxbridge, UK.ORCID 0000-0002-3673-3383
Emma C GoodallHealth Economics and Outcomes Research, GlaxoSmithKline plc, Mississauga, ON, Canada.ORCID 0000-0001-5647-4123
Kerigo NdiranguICON Health Economics, ICON plc, New York, NY, USA.
Gerard CrinerLewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Mark DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA.
David Mg HalpinDepartment of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter, UK.
MeiLan K HanUniversity of Michigan, Pulmonary and Critical Care, Ann Arbor, MI, USA.
David A LomasUCL Respiratory, University College London, London, UK.

Funding

Medical Research Council MR/N024842/1
6 · The paper itself

Abstract

Background: We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive pulmonary disease (COPD) (NCT02164513). Methods: Baseline inputs and treatment effects from IMPACT were populated into the validated GALAXY-COPD disease progression model. Canadian unit costs and drug costs (Canadian dollars [C$], 2017) were applied to healthcare resource utilization and treatments. Future costs and health outcomes were discounted at 1.5% annually. Analyses were probabilistic, and outputs included exacerbation rates, costs, and life years (LYs) and quality-adjusted life years (QALYs) gained. Results: Compared with FF/VI and UMEC/VI over a lifetime horizon, the analyses predicted that treatment with FF/UMEC/VI resulted in fewer moderate and severe exacerbations, more LYs and more QALYs gained, with a small incremental cost. The base-case incremental cost-effectiveness ratio (ICER) per QALY gained was C$18,989 (95% confidence interval [CI]: C$14,665, C$25,753) versus FF/VI and C$13,776 (95% CI: C$9787, C$19,448) versus UMEC/VI. FF/UMEC/VI remained cost-effective versus both FF/VI and UMEC/VI in all sensitivity analyses, including in scenario analyses that considered different intervention and comparator discontinuation rates, and treatment effects for subsequent therapy. Conclusion: Treatment with FF/UMEC/VI was predicted to improve outcomes and be a cost-effective treatment option for patients with symptomatic COPD and a history of exacerbations compared with FF/VI or UMEC/VI, in Canada.

Indexed as

Drug CostsAdministration, InhalationAgedAndrostadienesBenzyl AlcoholsBronchodilator AgentsCanadaChlorobenzenesClinical Trials, Phase III as TopicCost-Benefit AnalysisDisease ProgressionDrug CombinationsFemaleHumansLungMaleAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug Combinationsfluticasone furoateGSK573719QuinuclidinesvilanterolCanadachronic obstructive pulmonary diseasecost-effectivenessquality-adjusted life yearssingle-inhaler triple therapy

Identifiers

PMID31819401
PMCPMC6890193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.